<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637973</url>
  </required_header>
  <id_info>
    <org_study_id>EmLiFa001</org_study_id>
    <nct_id>NCT02637973</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes</brief_title>
  <acronym>EmLiFa</acronym>
  <official_title>Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Deutsche Diabetes Forschungsgesellschaft e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of empagliflozin treatment on hepatocellular lipid content, liver energy
      metabolism and body composition will be investigated in a multicentre, prospective,
      placebo-controlled, double-blind, randomized, 2-arm parallel, interventional and exploratory
      pilot study in patients with newly diagnosed type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multicentre, prospective, placebo-controlled, double-blind, randomized, 2-arm
      parallel, interventional pilot study HCL and intramyocellular lipids (IMCL) will be
      quantified with 1H magnetic resonance (MR) spectroscopy. Hepatic ATP and inorganic phosphate
      (Pi) concentrations will be assessed with 31P MR spectroscopy (1). Whole-body and hepatic
      insulin sensitivity and metabolic flexibility will be measured by combining
      hyperinsulinemic-euglycemic pancreatic clamp tests with isotopic dilution of 6,6-2H2 glucose
      and indirect calorimetry as shown (2). Abdominal fat distribution will be quantified by MR
      imaging.

      Newly diagnosed patients with type 2 diabetes (T2D) will be randomly allocated to once daily
      25 mg empagliflozin (EMPA) or placebo for 24 weeks with a computer-generated random sequence
      and will be masked to the treatment assignment. Participants will visit the clinical research
      center at baseline, 12 weeks and 24 weeks for MRS and metabolic examinations, including blood
      sampling for hepato- and adipocytokines. Anthropometric parameters (body weight, waist
      circumference, total body fat, blood pressure) and glycemic control (HbA1C, fasting blood
      glucose, FBG) will be assessed at baseline and during monitoring visits every 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat content</measure>
    <time_frame>from baseline to 24 weeks</time_frame>
    <description>Change in liver fat content between baseline and 24 weeks measured with magnetic resonance spectroscopy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin, film-tablet, 25mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>25 mg once daily</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 75 years

          -  BMI&lt;45 kg/m2

          -  known diabetes duration up to 7 years

          -  6%≤HbA1c≤8%

          -  drug naïve - no previous antihyperglycemic treatment or one month washout period of
             treatment with oral glucose lowering drugs (no previous treatment with
             thiazolidinedione (TZD) drugs allowed)

          -  obtained written informed consent

        Exclusion Criteria:

          -  uncontrolled hyperglycaemia at screening (glucose level ≥240 mg/dl after an overnight
             fast, confirmed by a second measurement)

          -  acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to
             consent

          -  previous lower limb amputation

          -  severe lower limb infection/ulceration within 3 months prior to consent

          -  liver disease including chronic viral hepatitis (B or C), alcohol abuse,
             hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's
             disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver
             cirrhosis of any etiology

          -  AST or ALT &gt; 3 x ULN

          -  positive result on hepatitis B (HBs-AG), hepatitis C (HCV-AB), or HIV 1 and 2 test

          -  impaired kidney function (estimated glomerular filtration rate [eGFR]&lt;60
             mL/min/1.73m2) during screening

          -  structural and functional urogenital abnormalities, that predispose for urogenital
             infections

          -  gastrointestinal surgeries that induce chronic malabsorption

          -  history of cancer (except basal cell carcinoma) or treatment for cancer within 5 years

          -  blood dyscrasias or any disorders causing haemolysis or unstable erythrocytes

          -  treatment with antiobesity drugs 3 months prior to consent

          -  treatment with immunomodulatory drugs (oral steroids, antihistamines)

          -  change in dosage of thyroid hormones within 6 weeks of consent

          -  pregnancy, lactation period

          -  metal or magnetic implants, devices or objects inside of or on the body, which are not
             MRI compatible (according to MRT safety checklist in Appendix 11.3)

          -  claustrophobia

          -  cigarette smoking (non-smoker &lt; 1year), alcohol consumption (male &gt;30 g/d, female
             &gt;20g/d)

          -  drug abuse or psychiatric disease

          -  night-worker or circumstances not allowing normal day-night rhythm

          -  hypersensitivity to empagliflozin (or drugs of similar chemical structure) or any of
             the drug compounds

          -  pharmaceutical preparations with which interactions can be expected - amiloride,
             furosemide, indapamide, spironolactone, torasemide, triamterene

          -  use of anti-NASH drugs (vitamin E, ursodeoxycholic acid, S-adenosylmethionine,
             betaine, silymarin, gemfibrozil, anti-TNF therapies, probiotics) in the 3 months prior
             to randomization

          -  women of childbearing potential not using two adequate methods of contraception
             including a barrier method and a highly efficacious non-barrier method

          -  persons with any kind of dependency on the investigator or employed by the sponsor or
             investigator

          -  persons held in an institution by legal or official order

          -  participation in another trial in the last 10 weeks before randomization or planned
             participation during the trial period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://ddz.uni-duesseldorf.de</url>
    <description>More information about the EmLiFa001 study</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

